Memory Pharmaceuticals Reports Phase 1 Data For R4996/MEM 63908

Memory Pharmaceuticals Reports Phase 1 Data For R4996/MEM 63908
Memory Pharmaceuticals Corp. (Nasdaq: MEMY) announced positive results from its Phase 1 program for R4996/MEM 63908, a partial agonist of the nicotinic alpha-7 receptor being developed in collaboration with Roche for cognitive disorders such as Alzheimer's disease. The Phase 1 program enrolled over 130 subjects and included a single-ascending dose study, a food interaction study, a study in elderly volunteers and a multiple ascending dose study.

In Early Diagnosis Of Alzheimer's Disease, MRI Brain Scans Accurate
MRI scans that detect shrinkage in specific regions of the mid-brain attacked by Alzheimer's disease accurately diagnose the neurodegenerative disease, even before symptoms interfere with daily function, a study by the Florida Alzheimer's Disease Research Center (ADRC) in Miami and Tampa found.